Tenax heart failure drug fails Phase 3 test despite 49% drop in cardiac stress biomarker
TNX-103 misses its Phase 3 LEVEL endpoints as Tenax shares collapse. See why a 26.3-meter subgroup benefit could keep the program alive.
Pharma & Biotech